von Essen R
Medizinischen Klinik B, Stiftsklinik Augustinum München.
Z Gesamte Inn Med. 1987 Sep 1;42(17):486-91.
Numerous studies have demonstrated a high prevalence of coronary thrombi in the early hours of acute myocardial infarction leading to a complete occlusion of the coronary artery. Thrombolysis and reperfusion in the very early hours can preserve jeopardized myocardium from necrosis. Using intravenous streptokinase early reperfusion can be achieved in 50% of the patients with occluded coronary arteries. Using rt-PA and prourokinase reperfusion rate is 60 to 70%. Both agents have more fibrin-specific activity, therefore the risk of bleedings is reduced. However, thrombolytic treatment with early reperfusion seems to be just the first step. Further procedures (percutaneous transluminal coronary angioplasty = PTCA or early bypass surgery) have to be added to improve not only the short-term but also the long-term prognosis. If the ongoing randomized trials confirm a significant reduction in mortality due to reperfusion and improved ventricular function this "aggressive treatment" of the evolving myocardial infarction will change our strategy from a symptomatical to a more causal therapy.
大量研究表明,在急性心肌梗死发病后的最初数小时内,冠状动脉血栓的发生率很高,会导致冠状动脉完全闭塞。在极早期进行溶栓和再灌注可使濒危心肌免于坏死。使用静脉链激酶,50%的冠状动脉闭塞患者可实现早期再灌注。使用重组组织型纤溶酶原激活剂(rt-PA)和尿激酶原,再灌注率为60%至70%。这两种药物都具有更高的纤维蛋白特异性活性,因此出血风险降低。然而,早期再灌注的溶栓治疗似乎只是第一步。还必须增加进一步的治疗手段(经皮腔内冠状动脉成形术=PTCA或早期搭桥手术),以不仅改善短期预后,还改善长期预后。如果正在进行的随机试验证实再灌注可显著降低死亡率并改善心室功能,那么这种对进展性心肌梗死的“积极治疗”将使我们的治疗策略从对症治疗转变为更具病因针对性的治疗。